A Small Nonrule of 3 Compatible Fragment Library Provides High Hit Rate of Endothiapepsin Crystal Structures with Various Fragment Chemotypes

被引:87
作者
Koester, Helene [1 ]
Craan, Tobias [1 ]
Brass, Sascha [1 ]
Herhaus, Christian [2 ]
Zentgraf, Matthias [3 ]
Neumann, Lars [4 ]
Heine, Andreas [1 ]
Klebe, Gerhard [1 ]
机构
[1] Univ Marburg, Dept Pharmaceut Chem, D-35032 Marburg, Germany
[2] Merck KGaA, D-64293 Darmstadt, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach, Germany
[4] Proteros Biostruct, D-82152 Martinsried, Germany
关键词
X-RAY CRYSTALLOGRAPHY; PROTEIN-KINASE-B; MOLECULAR CHAPERONE HSP90; STRUCTURE-BASED DESIGN; LEAD DISCOVERY; CATALYTIC MECHANISM; BETA-SECRETASE; INHIBITORS; IDENTIFICATION; POTENT;
D O I
10.1021/jm200642w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug like molecules are defined by Lipinski's rule of 5, to characterize fragment thresholds, they have been reduced from 5 to 3 (Astex's rule of 3). They are applied to assemble fragment libraries, and providers use them to select fragments for commercial offer. We question whether these rules are too stringent to compose fragment libraries with candidates exhibiting sufficient room for chemical subsequent growing and merging modifications as appropriate functional groups for chemical transformations are required. Usually these groups exhibit properties as hydrogen bond donors/acceptors and provide entry points for optimization chemistry. We therefore designed a fragment library (364 entries) without strictly applying the rule of 3. For initial screening for endothiapepsin binding, we performed a biochemical cleavage assay of a fluorogenic substrate at 1 mM. "Hits" were defined to inhibit the enzyme by at least 40%. Fifty-five hits were suggested and subsequently soaked into endothiapepsin crystals. Eleven crystal structures could be determined covering fragments with diverse binding modes: (i) direct binding to the catalytic dyad aspartates, (ii) water-mediated binding to the aspartates, (iii) no direct interaction with the dyad. They occupy different specificity pockets. Only 4 of the 11 fragments are consistent with the rule of 3. Restriction to this rule would have limited the fragment hits to a strongly reduced variety of chemotypes.
引用
收藏
页码:7784 / 7796
页数:13
相关论文
共 66 条
[1]   Ligand efficiency indices as guideposts for drug discovery [J].
Abad-Zapatero, C ;
Metz, JT .
DRUG DISCOVERY TODAY, 2005, 10 (07) :464-469
[2]   PHENIX: a comprehensive Python']Python-based system for macromolecular structure solution [J].
Adams, Paul D. ;
Afonine, Pavel V. ;
Bunkoczi, Gabor ;
Chen, Vincent B. ;
Davis, Ian W. ;
Echols, Nathaniel ;
Headd, Jeffrey J. ;
Hung, Li-Wei ;
Kapral, Gary J. ;
Grosse-Kunstleve, Ralf W. ;
McCoy, Airlie J. ;
Moriarty, Nigel W. ;
Oeffner, Robert ;
Read, Randy J. ;
Richardson, David C. ;
Richardson, Jane S. ;
Terwilliger, Thomas C. ;
Zwart, Peter H. .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 :213-221
[3]   Analysis of crystal structures of aspartic proteinases: On the role of amino acid residues adjacent to the catalytic site of pepsin-like enzymes [J].
Andreeva, NS ;
Rumsh, LD .
PROTEIN SCIENCE, 2001, 10 (12) :2439-2450
[4]  
[Anonymous], MOL OP ENV MOE VERS
[5]   Discovery of a Novel Hsp90 Inhibitor by Fragment Linking [J].
Barker, John J. ;
Barker, Oliver ;
Courtney, Stephen M. ;
Gardiner, Mihaly ;
Hesterkamp, Thomas ;
Ichihara, Osamu ;
Mather, Owen ;
Montalbetti, Christian A. G. N. ;
Mueller, Annett ;
Varasi, Mario ;
Whittaker, Mark ;
Yarnold, Christopher J. .
CHEMMEDCHEM, 2010, 5 (10) :1697-1700
[6]   Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets [J].
Baurin, N ;
Aboul-Ela, F ;
Barril, X ;
Davis, B ;
Drysdale, M ;
Dymock, B ;
Finch, H ;
Fromont, C ;
Richardson, C ;
Simmonite, H ;
Hubbard, RE .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2004, 44 (06) :2157-2166
[7]   High-throughput crystallography for lead discovery in drug design [J].
Blundell, TL ;
Jhoti, H ;
Abell, C .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) :45-54
[8]   High-throughput X-ray crystallography for drug discovery [J].
Blundell, TL ;
Patel, S .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (05) :490-496
[9]   4,5-diarylisoxazole HSP90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer [J].
Brough, Paul A. ;
Aherne, Wynne ;
Barril, Xavier ;
Borgognoni, Jenifer ;
Boxall, Kathy ;
Cansfield, Julie E. ;
Cheung, Kwai-Miny J. ;
Collins, Ian ;
Davies, Nicholas G. M. ;
Drysdale, Martin J. ;
Dymock, Brian ;
Eccles, Suzanne A. ;
Finch, Harry ;
Fink, Alexandra ;
Hayes, Angela ;
Howes, Robert ;
Hubbard, Roderick E. ;
James, Karen ;
Jordan, Allan M. ;
Lockie, Andrea ;
Martins, Vanessa ;
Massey, Andrew ;
Matthews, Thomas P. ;
McDonald, Edward ;
Northfield, Christopher J. ;
Pearl, Laurence H. ;
Prodromou, Chrisostomos ;
Ray, Stuart ;
Raynaud, Florence I. ;
Roughley, Stephen D. ;
Sharp, Swee Y. ;
Surgenor, Allan ;
Walmsley, D. Lee ;
Webb, Paul ;
Wood, Mike ;
Workman, Paul ;
Wrightt, Lisa .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (02) :196-218
[10]   Studies leading to potent, dual inhibitors of bcl-2 and Bcl-xL [J].
Bruncko, Milan ;
Oost, Thorsten K. ;
Belli, Barbara A. ;
Ding, Hong ;
Joseph, Mary K. ;
Kunzer, Aaron ;
Martineau, Darlene ;
McClellan, William J. ;
Mitten, Michael ;
ng, Shi-Chu Ng ;
Nimmer, Paul M. ;
Oltersdorf, Tilman ;
Park, Cheol-Min ;
Petros, Andrew M. ;
Shoemaker, Alexander R. ;
Song, Xiaohong ;
Wang, Xilu ;
Wendt, Michael D. ;
Zhang, Haichao ;
Fesik, Stephen W. ;
Rosenberg, Saul H. ;
Elmore, Steven W. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) :641-662